News from ucb A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 29, 2020, 07:00 ET UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease

- UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive...


Jul 27, 2020, 07:00 ET UCB Half Year Report 2020

Revenue increased to € 2.6 billion and net sales to € 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively...


Jun 05, 2020, 07:00 ET UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

UCB announced today the acquisition of Engage Therapeutics, Inc. (Summit, N.J. (U.S.)), a clinical-stage pharmaceutical company developing Staccato®...


Apr 10, 2020, 09:00 ET Assemblée Générale des Actionnaires d'UCB

Le gouvernement belge a publié le 9 avril 2020 l'arrêté royal n°4 du 9 avril 2020 portant des dispositions diverses en matière de copropriété et de...


Apr 10, 2020, 09:00 ET UCB's General Meeting of Shareholders

On 9 April 2020, the Belgian Government has published the Royal Decree n°4 of 9 April 2020 on various provisions regarding legislation on...


Apr 02, 2020, 09:30 ET UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

UCB today announced that the acquisition of Ra Pharmaceuticals, Inc. has been successfully completed and Ra Pharma is now a wholly-owned subsidiary...


Feb 20, 2020, 07:00 ET UCB Full Year Report 2019

7:00 (CET) – regulated information – Revenue reached € 4.9 billion (+6%, +7% CER[1]) net sales increased to € 4.7 billion (+6%) Underlying...


Dec 12, 2019, 03:00 ET UCB : Les patients atteints d'ostéoporose pensent que leur pathologie est négligée par les autorités sanitaires et ne représente pas une priorité de santé publique

- Une nouvelle enquête révèle que 65% des femmes atteintes d'ostéoporose pensent que leur pathologie est négligée.1 - 58% ont déclaré que les...


Dec 12, 2019, 03:00 ET UCB: Los pacientes con osteoporosis creen que las autoridades descuidan su enfermedad

Según una encuesta realizada a cerca de un millar de mujeres afectadas - En nuestro país, hay más de 3 millones de personas que sufren osteoporosis,...


Dec 12, 2019, 03:00 ET UCB: Le pazienti affette da osteoporosi ritengono che la propria condizione sia trascurata e non sia considerata una priorità da parte delle autorità sanitarie

- La ricerca rivela che il 65% delle donne affette da osteoporosi intervistate ritiene che la propria condizione sia trascurata1 - Il 58% di loro ha...


Dec 12, 2019, 03:00 ET UCB: Osteoporose Patientinnen sind der Meinung, die Gesundheits-behörden würden ihre Krankheit vernachlässigen und zurückstufen

- Eine neue Umfrage ergibt, dass 65 % der Frauen mit Osteoporose der Meinung sind, ihre Krankheit werde vernachlässigt1 - 58 % meinten, die...


Dec 09, 2019, 19:45 ET UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class...


Nov 08, 2019, 09:10 ET UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

UCB, a global biopharmaceutical company, today announced important new rheumatology data being presented on CIMZIA® (certolizumab pegol) and...


Oct 17, 2019, 07:00 ET Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab

Regulated Information - Inside Information - UCB, a global biopharmaceutical company, today announced positive results from BE VIVID, the first of...


Oct 10, 2019, 07:00 ET UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

Regulated Information – Inside Information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger...


Sep 21, 2019, 16:51 ET Gli esperti considerano l'osteoporosi una vera e propria epidemia silenziosa che, secondo quanto emerso dal nuovo sondaggio pubblicato in data odierna, è trascurata e non adeguatamente affrontata

- Si stima che l'osteoporosi colpisca 200 milioni di persone in tutto il mondo1 e che provochi una frattura ogni 3 secondi2, eppure una recente...


Sep 20, 2019, 13:56 ET Los especialistas consideran que la osteoporosis es una epidemia silenciosa descuidada y desatendida

- Según una encuesta realizada en Europa, en la que ha participado España, Los especialistas consideran que la osteoporosis es una epidemia...


Sep 20, 2019, 13:36 ET Volgens nieuw onderzoek dat vandaag is gepubliceerd, wordt osteoporose door specialisten gezien als een stille epidemie die wordt verwaarloosd en waar nauwelijks aandacht voor bestaat.

- Naar schatting lijden wereldwijd 200 miljoen mensen aan osteoporose1 en resulteert dit om de 3 seconden in een breuk2, maar uit een nieuwe enquête...


Sep 20, 2019, 13:09 ET W opinii specjalistów osteoporoza jest cichą epidemią, która jest niedoceniana i wobec której nie są podejmowana odpowiednie działania, jak wskazują opublikowane dzisiaj wyniki badania ankietowego

- Szacuje się, że osteoporoza dotyka 200 milionów osób na całym świecie1 i jest przyczyną występowania złamania kości co 3 sekundy2. Mimo takich...


Sep 20, 2019, 13:07 ET Experten erachten Osteoporose als eine stille Epidemie, die vernachlässigt und unzureichend behandelt wird, besagt eine neue, heute veröffentlichte Umfrage

- Osteoporose betrifft geschätzte 200 Millionen Personen weltweit1 und führt alle 3 Sekunden2 zu einer Fraktur. Dennoch zeigt eine neue Umfrage, dass ...


Sep 20, 2019, 13:03 ET Les experts considèrent l'ostéoporose comme une maladie silencieuse négligée et insuffisamment traitée

- On estime que l'ostéoporose touche 200 millions de personnes dans le monde1 et qu'elle est à l'origine d'une fracture toutes les 3 secondes2 ;...


Jul 25, 2019, 07:00 ET UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers

– Regulated information – Revenue reached € 2.3 billion (+2%, +4% CER1) net sales increased to € 2.2 billion (+3%, +5% CER – adjusted2 +11%, +7% CER) ...


Mar 02, 2019, 07:00 ET Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

UCB, a global biopharmaceutical company, presented positive data from the Phase 2b BE ABLE extension study of bimekizumab in patients with...


Feb 28, 2019, 13:55 ET UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline

"We are confident for the future growth of UCB based on strong delivery in 2018, marking the fifth year of profitable growth in a row and a new...


Nov 30, 2018, 08:00 ET UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership

UCB is excited to be presenting 20 abstracts at this year's American Epilepsy Society Meeting, taking place between November 30 and December 4 in New ...